18F-FDG PET/CT 显示免疫检查点抑制剂相关腹膜后脂膜炎
一例71岁女性未分化肺腺癌术后出现骨及肾上腺转移,接受抗PD-1免疫检查点抑制剂(ICI)治疗后达完全肿瘤缓解;
要点
- 抗PD-1治疗后达完全缓解者随访PET/CT可新发腹膜后及皮下脂肪高代谢。
- 脂肪影高摄取伴邻近筋膜轻度增厚,需结合ICI用药时序判读为免疫相关不良事件。
- 糖皮质激素治疗有效支持ICI相关脂膜炎的诊断。
核心结论
- 18F-FDG PET/CT可显示ICI治疗相关的腹膜后及皮下脂膜炎,表现为脂肪影高摄取伴邻近筋膜轻度增厚。
主要发现
- 随访18F-FDG PET/CT证实肿瘤完全缓解,同时见腹膜后及皮下脂肪影高放射性示踪剂摄取,邻近筋膜轻度增厚。
关键数值与推荐
- 结合ICI治疗时序、肿瘤缓解及糖皮质激素治疗有效,判定为ICI相关不良事件。
临床怎么用
- 对ICI治疗后达肿瘤缓解者,PET/CT新发脂肪高代谢伴筋膜增厚时应警惕免疫相关脂膜炎,避免误判为转移。
局限性
- 单例病例报告,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 71-year-old woman was operated on for undifferentiated lung adenocarcinoma. Four months after surgery, she developed bone and adrenal metastases. She underwent palliative radiation therapy of left scapula and right iliac bone. Thereafter, she started immune checkpoint inhibitor (ICI) therapy with anti-PD-1 antibodies achieving complete tumor response. Twenty months later, a follow-up 18F-FDG PET/CT confirmed tumor response and revealed high radiotracer accumulation in correspondence of retroperitoneal and subcutaneous fat opacities. The contiguous fasciae were mildly thickened. The temporal relation with ICI therapy together with tumor response and corticosteroids therapy effectiveness led to conclude for ICI-related adverse events.
引用
- Minutoli F, Parisi S, Laudicella R, et al. 18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis". Clin Nucl Med. 2022. PMID: 34269732. doi:10.1097/RLU.0000000000003806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。